Denali Q2 2026 earnings: AVLAYAH debuts with $3.6 million in revenue

Denali Therapeutics (NASDAQ: DNLI) reported Q2 2026 net product revenue of $3.6 million, compared with no revenue a year earlier, while diluted net loss per share improved to $0.68 from $0.72. AVLAYAH’s first full commercial quarter established a new revenue stream, although net loss widened to $127.6 million as interest and other income declined.

Core financial results

The quarter marked Denali’s transition into a commercial-stage biotechnology company following AVLAYAH’s U.S. approval in March 2026. The expense mix also shifted: research and development spending declined, while selling, general and administrative expenses increased to support the launch.

All figures below are GAAP results for the three months ended June 30.

Business and pipeline performance

AVLAYAH begins commercial rollout

AVLAYAH generated $3.6 million of net product revenue during its first full quarter of commercial availability. Denali said initial interest in starting treatment was ahead of its internal expectations, although the release did not provide patient-start or prescription figures.

Commercial policies covering AVLAYAH represented more than 50% of covered lives by the reporting date, while 14 state Medicaid programs had published coverage. Denali also said its launch activities had reached approximately 80% of healthcare organizations treating eligible MPS II patients.

The ongoing Phase 2/3 COMPASS study is intended to provide confirmatory evidence for AVLAYAH’s accelerated approval, support a potential U.S. label expansion to adults and contribute to future global regulatory submissions.

Multiple clinical milestones move into 2027

Denali’s pipeline now includes two clinical-stage Alzheimer’s disease programs based on its TransportVehicle platform, but most of the next major data releases are scheduled for 2027.

• Zafinofusp alfa: Phase 3 start-up activities are underway, with a biologics license application submission and potential accelerated approval targeted for 2027.
• DNL593: Enrollment in the 40-participant Phase 1/2 study is complete. Results are now expected in 2027 rather than by the end of 2026, allowing a longer observation period for biomarkers such as neurofilament light chain. Takeda terminated its collaboration on the program for strategic reasons that Denali said were unrelated to safety or efficacy.
• DNL952: Dosing in late-onset Pompe disease began during Q2, with initial clinical data expected in 2027.
• DNL628 and DNL921: Initial DNL628 biomarker data are expected in the first half of 2027, while DNL921 safety and proof-of-concept data are expected during 2027.
• DNL151: The Phase 2b LUMA study did not meet its primary or secondary endpoints, leading Denali and Biogen to discontinue development in idiopathic Parkinson’s disease. Denali’s genetically selected Phase 2a BEACON study continues, with data expected in the first half of 2027.

Profitability and balance sheet

R&D expense decreased by $5.7 million, mainly because of lower spending on small-molecule programs and reduced clinical costs for tividenofusp alfa. SG&A expense rose by $4.0 million, primarily due to increased headcount supporting the AVLAYAH launch.

Based on reported revenue and cost of goods sold, Q2 gross profit was about $3.5 million and gross margin was approximately 97.4%. That margin is not representative of normalized commercial economics because manufacturing costs incurred before FDA approval were previously expensed as R&D. Cost of goods sold will reflect a higher average per-unit cost after that inventory is used.

Cash, cash equivalents and marketable securities totaled approximately $940 million at June 30, 2026. Denali subsequently received $195 million of gross proceeds from selling its Priority Review Voucher in July, bringing pro forma cash, cash equivalents and marketable securities to more than $1.1 billion. The proceeds were received after quarter-end and therefore were not included in the June 30 balance.

Lower interest income widened the net loss while a higher share count improved EPS

Denali’s operating loss narrowed by approximately $4.4 million because total operating expenses declined slightly while product revenue began. However, net loss widened by approximately $3.4 million because interest and other income fell to $3.0 million from $10.8 million.

Diluted loss per share still improved to $0.68 because the weighted-average diluted share count increased to 187.3 million from 171.4 million, an increase of approximately 9.3%. The lower per-share loss therefore did not reflect an improvement in bottom-line profitability.

Guidance

Denali projects a clear sequential increase in AVLAYAH sales for the third quarter, supported by growing physician engagement and payer access. The guidance applies specifically to AVLAYAH net product revenue rather than total company revenue.

Recent insider transactions

The supplied transaction records show two direct insider sales on January 6, 2026. These transactions should be viewed as reported activity without inferring the insiders’ outlook for the company.

Risks investors need to watch

• Commercial execution remains early: AVLAYAH revenue is still small relative to Denali’s quarterly operating expense base, making patient starts, reimbursement access and the Q3 revenue trajectory important measures of launch progress.
• Accelerated approval requires follow-through: Continued approval and potential label expansion depend on confirmatory evidence from the COMPASS study and subsequent regulatory decisions.
• Clinical development remains uncertain: DNL151’s failed LUMA study and discontinuation in idiopathic Parkinson’s disease illustrate the risk that other investigational programs may not produce successful results.
• Several catalysts have shifted into 2027: The revised DNL593 timing and concentration of other readouts in 2027 increase exposure to trial execution and data delays.
• Initial gross margin is temporarily elevated: Previously expensed inventory lowered Q2 cost of goods sold, so future product margins may decline as that inventory is depleted.

Summary

Denali’s Q2 2026 results were defined by AVLAYAH’s first full commercial quarter and the beginning of product revenue. Lower R&D spending helped narrow the operating loss, but reduced interest income caused the net loss to widen, while launch-related hiring raised SG&A. The next operating test is whether AVLAYAH can reach its Q3 revenue guidance as payer access expands, while the pipeline’s confirmatory studies and 2027 clinical readouts remain central to the longer-term outlook.